Selective P-glycoprotein (Pgp) inhibitor. Effectively reverses Pgp mediated drug resistance in NCI/ADR cells, but has no effect on the drug sensitivities of MCF-7/VP cells that overexpress MRP1.
Product Details
| Alternative Name: | N-(1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide |
| |
| Formula: | C26H23N3O |
| |
| MW: | 393.5 |
| |
| CAS: | 365565-02-2 |
| |
| Purity: | ≥93% |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in methanol, 100% ethanol (3mg/ml) or DMSO (20mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-: B.D. Lee, et al.; J. Med. Chem.
47, 1413 (2004),
Abstract;
Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008: B.D. Lee, et al.; Oncol. Res.
14, 49 (2003),
Abstract;
